Bendamustine Hydrochloride

• DALY II USA/MB-CART2019.1 for DLBCL Pending
  2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
• A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending
  2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
• A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer Pending
  2025-523276-23-00 Phase I (FiH) 2 countries Novartis Pharma AG
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending
  2025-524241-27-00 Phase III 5 countries Innocare Pharma Inc.
• A clinical trial of MK-1045 and rituximab in people with follicular lymphoma (MK-1045-007) Recruiting
  2025-522777-10-00 Phase II/III 2 countries Merck Sharp & Dohme LLC
• A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting
  2025-522669-32-00 Phase III 2 countries Dizal Pharmaceutical Co. Ltd.
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting
  2022-502660-20-00 Phase III 8 countries Regeneron Pharmaceuticals Inc.
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting
  2024-519152-82-00 Phase III 8 countries Celgene Corp.
• A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting
  2024-518893-15-00 Phase III 5 countries BeOne Medicines AG
• A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), whi… Recruiting
  2024-516605-23-00 Phase III 9 countries Secura Bio Limited
• IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting
  2024-519790-19-00 Phase I (FiH) 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting
  2023-505436-35-00 Phase III 6 countries Lysarc
• Phase I/IIa multicentre study of infusion of autologous peripheral blood T lymphocytes expanded and genetically modified using Sleeping Beau… Recruiting
  2024-514544-90-00 Phase I/II 1 country Fundacion De Investigacion Biomedica De Salamanca
• A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting
  2023-503206-37-00 Phase III 4 countries F. Hoffmann-La Roche AG
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting
  2022-501810-77-00 Phase III 5 countries Lysarc
• phase I/II b study of atezolizumab and BEGEV as first salvage treatment in patients with relapsed or refractory Hodgkin’s lymphoma candidate… Recruiting
  2024-511631-10-00 Phase I/II 1 country Fondazione Italiana Linfomi Ets
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C… Recruiting
  2022-502646-27-00 Phase II/III 5 countries Merck Sharp & Dohme LLC
• Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin… Ended
  2024-515624-36-00 Phase I (FiH) 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
• A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended
  2024-511304-16-00 Phase II 5 countries Celgene Corp.
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended
  2023-503452-27-00 Phase III 7 countries Novartis Pharma AG
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L… Ended
  2024-511594-30-00 Phase III 4 countries Kite Pharma Inc.
• Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi i… Ended
  2024-511633-35-00 Phase II 1 country Fondazione Italiana Linfomi Ets
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended
  2024-511599-33-00 Phase III 10 countries Loxo Oncology Inc.

Showing 1–24 of 39 trials